Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District

Open Access Macedonian Journal of Medical Sciences
Uwe WollinaTorello Lotti

Abstract

Anastrozole is a non-selective aromatase inhibitor for adjuvant breast cancer therapy in postmenopausal women. Cutaneous adverse events have been reported. We observed a 64-year-old female patient with a medical history of locally advanced breast cancer of her right breast that was treated with radiotherapy and adjuvant drug therapy with anastrozole. She developed a segmental bullous eruption limited to the cancer-affected breast. Cessation of the aromatase inhibitor and systemic therapy with prednisolone cleared the lesions completely. This is the first report of a segmental erythema multiforme like drug eruption by anastrozole and another example of the concept of the immunocompromised district of skin.

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Related Papers

Breast Cancer : the Journal of the Japanese Breast Cancer Society
Yasuaki SagaraTsutomu Douchi
Journal of the American Academy of Dermatology
Diya F Mutasim, Jennifer L Baumbach
Archives of Dermatology
H S Yaffee
© 2022 Meta ULC. All rights reserved